Anti-cytokine therapy in rheumatoid arthritis (Q40963908)

25 September 2017

1 reference

title

Anti-cytokine therapy in rheumatoid arthritis (English)

1 reference

25 September 2017

Elliott MJ

1

1 reference

PubMed ID

8591646

25 September 2017

Maini RN

series ordinal

2

1 reference

25 September 2017

1 November 1995

1 reference

Bailliere's clinical rheumatology

25 September 2017

1 reference

25 September 2017

9

1 reference

25 September 2017

4

1 reference

25 September 2017

633-652

1 reference

Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis

25 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Circadian rhythm of serum interleukin-6 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Cells with dendritic morphology and bright interleukin-1 alpha staining circulate in the blood of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

The acute phase response

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Arthritis induced by interleukin-1 is dependent on the site and frequency of intraarticular injection

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Modalities for reducing interleukin 1 activity in disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Spontaneous release of angiotensin converting enzyme and interleukin 1 beta from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Tumor necrosis factor receptor-mediated signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Cytokine inter-relationships and their association with disease activity in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Humanised monoclonal antibody therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Constitutive production of interleukin-6 and immunologic features in cardiac myxomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Immunoregulatory role of interleukin 10 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Interleukin-6 and its receptor: a paradigm for cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

The control of antibody production by immunomodulatory molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Immunological intervention reveals reciprocal roles for tumor necrosis factor-alpha and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Production of IL-1 and IL-1 receptor antagonist and the pathological significance in lipopolysaccharide-induced arthritis in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Interleukin 6 inhibits delayed-type hypersensitivity and the development of adjuvant arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Production and modulation of interleukin 6 synthesis by synoviocytes derived from patients with arthritic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Induction of an acute erosive monarticular arthritis in mice by interleukin-1 and methylated bovine serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Inactivation of interleukin-1 beta converting enzyme by peptide (acyloxy)methyl ketones

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Tumor necrosis factor, other cytokines and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

The pathophysiology of tumor necrosis factors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

The use of monoclonal antibodies to achieve immunological tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

1 reference

7 January 2021

The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980306-1

7 January 2021

10.1016/S0950-3579(05)80306-1

Identifiers

DOI

1 reference

25 September 2017

1 reference

PubMed ID

8591646